AstraZeneca is starting a new clinical trial evaluating how one of our existing medicines might help alleviate the exaggerated immune response that can result in pneumonia, respiratory failure and death of patients hospitalised with COVID-19 infections. The trial design is based upon strong scientific evidence supporting the role of the Bruton’s tyrosine kinase (BTK) pathway in the production of inflammatory cytokines, and on encouraging early clinical data.
This trial will assess how one of our existing medicines might help alleviate the “cytokine storm” associated with the disease – when the immune system can overreact and attack vital organs like the lungs and the liver.
This large, multicentre, global, randomised trial uses a two-part patient-centric design developed in record time to accelerate data capture and analysis. José Baselga, Executive Vice President, Oncology R&D, said: “With this trial we are responding to the novel insights of the scientific community and hope to demonstrate that adding our medicine to best supportive care reduces the need to place patients on ventilators and improves their chances of survival. This is the fastest launch of any clinical trial in the history of AstraZeneca.”
Read more: https://www.astrazeneca.com/media-centre/articles/2020/investigating-an-existing-medicine-as-a-potential-treatment-for-covid-19.html#!